Jung, Psychedelic Therapy, and the Desire for Transcendence

by Brenton L. Delp

The renewed interest in psychedelic and ketamine therapy should not be dismissed as mere fashion, nor should it be welcomed as a new miracle. It belongs to something much deeper in the modern soul. It arises at the point where ordinary therapeutic language often fails, where insight no longer moves the body, where the person understands the pattern but remains trapped inside it, where despair, compulsion, trauma, and self-enclosure have become circular. The promise of these therapies is not simply that they may reduce symptoms. The deeper promise is that they may interrupt a loop.

This is why they matter for addiction. Addiction is not merely appetite. It is not merely pleasure-seeking. It is a closed circuit of relief, return, shame, repetition, and necessity. The addicted person does not simply choose the substance. The substance becomes the false solution to an unbearable structure of existence. It offers immediacy where life requires mediation. It offers certainty where the soul lives in ambiguity. It offers relief where no larger form has yet been built. Addiction is, in this sense, a desperate metaphysics. It is the attempt to solve the problem of suffering chemically.

Psychedelic and ketamine therapies enter the scene because they appear to do something ordinary consciousness often cannot do for itself. They break continuity. They loosen the grip of the habitual self. They can suspend, for a time, the closed identity that says: this is who I am, this is what I need, this is what I always do, this is what I cannot escape. In depression, trauma, and addiction, the person often does not suffer only from pain. The person suffers from imprisonment in a world that has become too small. The same thoughts return. The same shame returns. The same hunger returns. The same hopelessness returns. The person does not merely have symptoms; the person has become organized around them.

C. G. Jung saw the danger of this problem long before the contemporary psychedelic renaissance. His concern was not simply that drugs produce unusual experiences. Jung knew that the unconscious could overwhelm the ego even without drugs. His concern was that chemically induced revelation might arrive without the slow preparation, symbolic labor, moral seriousness, and psychic integration required to bear it. In a 1955 letter to A. M. Hubbard, Jung acknowledged that mescaline was of great psychological interest, but he warned that it could uncover psychic material “at any time and place,” regardless of whether the individual was mature enough to integrate it. He then gave the formulation that still matters: “Mescalin is a short cut.”¹

That sentence should govern the entire discussion. Jung did not deny that the drug could open the psyche. He feared precisely that it could open the psyche too easily. Active imagination, analysis, dream work, religious discipline, and symbolic life expose the person to unconscious material through a process. Psychedelic experience can collapse process into event. It can produce vision before character. It can grant encounter before integration. It can give the person access to a depth for which no corresponding form of life has yet been built.

This is where the evidence becomes important, but also where evidence must be interpreted carefully. Esketamine has moved further into regulated psychiatry than classic psychedelics. The FDA label for Spravato indicates its use for treatment-resistant depression in adults, including as monotherapy or with an oral antidepressant, and also for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior when used with an oral antidepressant. But the same label also makes clear that this is not casual medicine: sedation, dissociation, blood pressure elevation, abuse risk, respiratory depression, and required medical monitoring are central parts of the treatment reality.² Psychedelics such as psilocybin and MDMA remain more complicated. The FDA has issued guidance for psychedelic clinical trials because these substances create unusual methodological and safety problems, including blinding, expectancy, abuse potential, and the difficulty of separating drug effect from therapeutic setting.³

For addiction specifically, the psilocybin alcohol-use-disorder study is among the most suggestive. In a randomized clinical trial of ninety-three participants, psilocybin-assisted psychotherapy produced significantly lower heavy drinking days over thirty-two weeks compared with active placebo and psychotherapy.⁴ That finding should be taken seriously. But it should not be inflated into a doctrine of salvation. The study does not prove that psilocybin “cures addiction.” It suggests that, under structured therapeutic conditions, a powerful altered state may help interrupt addictive repetition and allow a different relationship to drinking to become possible.

That distinction is everything. Addiction does not end because a person has an experience. Addiction ends, if it ends, because the person builds a different form of life. A psychedelic experience may reveal the prison. It may even open the door. But it does not teach the person how to live outside the prison. It does not pay the rent, repair the marriage, endure grief, restore discipline, rebuild the body, tolerate boredom, face guilt, or sustain obligation after the intensity fades. The danger is that the psychedelic experience itself becomes another absolute: another event around which the person organizes hope, another promise that suffering can be bypassed rather than borne, another substitute for moral reconstruction.

Jung’s later letters deepen this concern. In his 1954 letter to Father Victor White, written in response to questions about LSD and mescaline, Jung warned against wanting more of the collective unconscious than one receives through dreams and intuitions. The unconscious, once made conscious, does not merely entertain the mind. It becomes task, responsibility, burden. Jung’s suspicion of Aldous Huxley was based on this same fear. Huxley, in Jung’s view, risked becoming a sorcerer’s apprentice: able to call up the spirits, but not necessarily able to dismiss or integrate them.⁵ The image is exact. The danger is not only illusion. The danger is invocation without mastery.

This is the central danger: psychedelic therapy can become anti-addictive in one context and addictive in another. Not necessarily addictive in the narrow pharmacological sense, but addictive in the symbolic sense. It can become the search for the next breakthrough, the next ceremony, the next vision, the next ego death, the next revelation, the next chemically mediated encounter with meaning. The person may stop worshiping alcohol, opioids, food, sex, rage, or despair only to begin worshiping transformation itself. The object changes. The structure remains.

From the standpoint of The Logic of Addiction, the question is therefore not simply, “Do these therapies work?” The question is: what kind of work do they do, and what do they leave undone? They may loosen rigid patterns. They may expose grief. They may permit emotional contact where ordinary therapy has become intellectualized. They may allow the person to experience the self as less fixed, less condemned, less identical with its wound. They may produce awe, forgiveness, mourning, humility, and a temporary release from the tyranny of the compulsive self. These are not small things. For some people, they may be life-altering.

But they remain openings, not completions. The soul does not become whole because it has seen unity. The addict does not recover because he has glimpsed love. The traumatized person is not healed because she has touched an image beyond fear. The depressive does not become free because, for six hours, the world became luminous. These experiences may matter precisely because they reveal that another relation to existence is possible. But possibility is not yet actuality. The vision must descend into habit. The revelation must become practice. The opening must become form.

This is why integration is not an accessory to psychedelic therapy. It is the ethical center of the whole matter. Without integration, the experience remains an event. With integration, it may become part of a life. Integration means that the person must ask: What did this experience demand of me? What must now change? What responsibility did I avoid? What grief did I finally touch? What lie did I see through? What relationship must be repaired? What pattern must be refused? What form of endurance must now be practiced without chemical assistance?

Jung’s letter to Betty Grover Eisner in 1957 makes this point with unusual sharpness. Eisner had been one of the early psychologists interested in LSD therapy, and she believed the drug might open the unconscious and accelerate processes Jung associated with individuation. Jung resisted this conclusion. Religious visions produced by drugs, he argued, have more to do with physiology than with religion. Religion, for Jung, was not a vision but a way of life, a devotion, a submission to realities greater than the ego. It could not be “injected by a syringe” or “swallowed in the form of a pill.”⁶ The language may sound severe, but the underlying distinction is crucial: the image of transformation is not yet transformation.

The deepest therapeutic danger is not that these substances produce illusion. Sometimes they may break illusion. The deeper danger is that modern people, exhausted by symptom and disenchanted with ordinary life, will ask them to do what no medicine can do: redeem existence. That is the old religious hunger returning under neurological and therapeutic language. The clinic replaces the church. The session replaces the sacrament. The guide replaces the priest. The experience replaces grace. But the underlying desire remains: to be delivered from the burden of becoming human.

This does not mean the therapies are false. It means they must be placed within a larger anthropology. Human beings do not need only altered states. They need forms of life capable of carrying suffering. They need community, work, responsibility, mourning, forgiveness, embodiment, discipline, and symbolic orientation. They need ways to suffer that do not immediately become compulsion. They need rituals that do not collapse into consumption. They need therapy that does not promise exemption from tragedy. They need medicine that knows it is medicine, not salvation.

The failure of many addiction treatments is that they underestimate the metaphysical hunger inside addiction. They treat the substance as the problem while leaving untouched the fact that the substance has become the person’s answer to existence. Psychedelic and ketamine therapies may be useful precisely because they can disturb that answer. They may show that alcohol is not God, that despair is not truth, that trauma is not identity, that craving is not destiny, that the self is not identical with its wound. But after that disturbance comes the harder question: if the old absolute is false, what now?

This is also where Jung’s caution and the modern evidence can be brought together. The emerging research does not require us to dismiss psychedelic or ketamine therapy. It requires us to refuse magical thinking about them. A drug may create an opening. It may loosen the defensive organization of the self. It may allow grief, memory, guilt, terror, or love to become accessible. But what becomes accessible must still be carried. What is revealed must still be interpreted. What is touched must still be lived. The experience must be brought back into speech, relationship, habit, responsibility, and time.

Recovery begins where the miracle ends. This is the sentence that should govern the entire conversation. The experience may open the door, but life must still be built on the other side. The person must still learn how to wake, work, eat, apologize, remember, grieve, resist, pray or not pray, love, fail, return, and endure. No medicine can eliminate this task. No vision can replace it. No chemical opening can become a substitute for the slow, difficult formation of a soul.

The proper place of psychedelic and ketamine therapy, then, is neither dismissal nor worship. They belong among the possible tools of interruption. They may help some people break the spell of repetition long enough to imagine another life. But they become dangerous when marketed as shortcuts to wholeness. Jung’s warning remains decisive here. The unconscious may be opened, but opening is not integration. Vision may arrive, but vision is not individuation. The religious image may appear, but religion, in the deeper sense, is a way of life.

The addicted person does not need another absolute. The addicted person needs freedom from false absolutes, and then the patient construction of a life no longer organized around relief. At best, these therapies may interrupt the loop. They may create an opening in despair. They may loosen the compulsive identity. They may allow suffering to become speakable. But they do not by themselves build a life. That remains the human task.

Notes

1. C. G. Jung, letter to A. M. Hubbard, 15 February 1955, in C. G. Jung: Letters, Volume II: 1951–1961, ed. Gerhard Adler and Aniela Jaffé, trans. R. F. C. Hull (Princeton: Princeton University Press, 1975), 222–224.
2. U.S. Food and Drug Administration, Spravato (esketamine) Nasal Spray Prescribing Information, revised 2025.
3. U.S. Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, guidance for industry, 2023.
4. Michael P. Bogenschutz et al., “Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial,” JAMA Psychiatry 79, no. 10 (2022): 953–962.
5. C. G. Jung, letter to Victor White, 10 April 1954, in C. G. Jung: Letters, Volume II: 1951–1961, 172–173.
6. C. G. Jung, letter to Betty Grover Eisner, 12 August 1957, in C. G. Jung: Letters, Volume II: 1951–1961, 382–383.